Effects of advanced glycation end products on calcium handling in cardiomyocytes. 2014

Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
Department of Endocrinology, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.

OBJECTIVE Advanced glycation end products (AGEs) accumulate in diabetes and the engagement of receptor for AGE (RAGE) by AGEs contributes to the pathogenesis of diabetic cardiomyopathy. This study aims to investigate the effects of AGE/RAGE on ryanodine receptor (RyR) activity and Ca(2+) handling in cardiomyocytes to elucidate the possible mechanism underlying cardiac dysfunction in diabetic cardiomypathy. RESULTS Confocal imaging Ca(2+) spark, the elementary Ca(2+) release event reflecting RyR activity in intact cell, as well as SR Ca(2+) content and systolic Ca(2+) transient were performed in cultured neonatal rat ventricular myocytes. The results show that 50 mg/ml AGE increased the frequency of Ca(2+) sparks by 160%, while 150 mg/ml AGE increased it by 53%. AGE decreased the amplitude, width and duration of Ca(2+) sparks. Blocking RAGE with anti-RAGE IgG completely abolished the alteration of Ca(2+) sparks. The SR Ca(2+) content indicated by the amplitude (ΔF/F0) of 20 mM caffeine-elicited Ca(2+) transient was significantly decreased by 150 mg/ml AGE. In parallel, the amplitude of systolic Ca(2+) transient evoked by 1 Hz-field stimulation was remarkably decreased by 150 mg/ml AGE. The anti-RAGE antibody completely restored the impaired SR load and systolic Ca(2+) transient. CONCLUSIONS AGE/RAGE signal enhanced Ca(2+) spark-mediated SR Ca(2+) leak, causing partial depletion of SR Ca(2+) content and consequently decreasing systolic Ca(2+) transient, which may contribute to contractile dysfunction in diabetic cardiomyopathy.

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008297 Male Males
D008665 Metalloporphyrins Porphyrins which are combined with a metal ion. The metal is bound equally to all four nitrogen atoms of the pyrrole rings. They possess characteristic absorption spectra which can be utilized for identification or quantitative estimation of porphyrins and porphyrin-bound compounds. Metalloporphyrin
D009200 Myocardial Contraction Contractile activity of the MYOCARDIUM. Heart Contractility,Inotropism, Cardiac,Cardiac Inotropism,Cardiac Inotropisms,Contractilities, Heart,Contractility, Heart,Contraction, Myocardial,Contractions, Myocardial,Heart Contractilities,Inotropisms, Cardiac,Myocardial Contractions
D011971 Receptors, Immunologic Cell surface molecules on cells of the immune system that specifically bind surface molecules or messenger molecules and trigger changes in the behavior of cells. Although these receptors were first identified in the immune system, many have important functions elsewhere. Immunologic Receptors,Immunologic Receptor,Immunological Receptors,Receptor, Immunologic,Receptors, Immunological
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002121 Calcium Channel Blockers A class of drugs that act by selective inhibition of calcium influx through cellular membranes. Calcium Antagonists, Exogenous,Calcium Blockaders, Exogenous,Calcium Channel Antagonist,Calcium Channel Blocker,Calcium Channel Blocking Drug,Calcium Inhibitors, Exogenous,Channel Blockers, Calcium,Exogenous Calcium Blockader,Exogenous Calcium Inhibitor,Calcium Channel Antagonists,Calcium Channel Blocking Drugs,Exogenous Calcium Antagonists,Exogenous Calcium Blockaders,Exogenous Calcium Inhibitors,Antagonist, Calcium Channel,Antagonists, Calcium Channel,Antagonists, Exogenous Calcium,Blockader, Exogenous Calcium,Blocker, Calcium Channel,Blockers, Calcium Channel,Calcium Blockader, Exogenous,Calcium Inhibitor, Exogenous,Channel Antagonist, Calcium,Channel Blocker, Calcium,Inhibitor, Exogenous Calcium
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000067759 Receptor for Advanced Glycation End Products A single-pass transmembrane CELL SURFACE RECEPTOR that binds ADVANCED GLYCATION END PRODUCTS to mediate cellular responses to both acute and chronic vascular inflammation in conditions such as ATHEROSCLEROSIS and DIABETES MELLITUS, TYPE 2. Advanced Glycation End Product Receptor,Advanced Glycation End Product Receptors,Receptor For Advanced Glycation End Product,Receptor for Advanced Glycation Endproduct,AGE Receptor,AGER Protein,Amphoterin Receptor,RAGE (Receptor for Advanced Glycation End Products),Receptor for Advanced Glycation End Products (RAGE),Receptor for Advanced Glycation Endproducts,Receptor, Amphoterin

Related Publications

Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
September 2021, Biochemical and biophysical research communications,
Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
January 2011, Contributions to nephrology,
Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
February 2019, Scientific reports,
Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
April 2003, The American journal of pathology,
Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
July 2017, The Journal of allergy and clinical immunology,
Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
January 2015, International journal of endocrinology,
Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
April 2008, Acta medica Okayama,
Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
April 2022, Oral diseases,
Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
January 2023, Nutrients,
Dewen Yan, and Xinping Luo, and Yali Li, and Wenjuan Liu, and Jianxin Deng, and Na Zheng, and Kaiping Gao, and Qiaobing Huang, and Jie Liu
May 2007, Spine,
Copied contents to your clipboard!